A previous study found that different genes might respond differently to induction chemotherapy in adult AML [19], for example, epigenetic regulators such as DNMT3A or TET2 are likely to persist during clinical remission, whereas somatic mutations that activate signaling pathways are usually cleared. The gene discussed is TET2; the disease is acute myeloid leukemia.